Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Moderate Buy” by Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.56.

A number of equities research analysts have weighed in on MRVI shares. Royal Bank of Canada lifted their target price on Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Stifel Nicolaus reduced their price target on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Finally, Craig Hallum initiated coverage on Maravai LifeSciences in a research report on Wednesday. They set a “buy” rating and a $15.00 price objective on the stock.

Maravai LifeSciences Price Performance

Shares of Maravai LifeSciences stock opened at $8.60 on Thursday. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -9.56 and a beta of 0.01. The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.41 and a current ratio of 8.00. The stock has a 50 day moving average price of $7.19 and a 200-day moving average price of $6.81. Maravai LifeSciences has a one year low of $4.52 and a one year high of $16.62.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. The firm had revenue of $74.14 million for the quarter, compared to analysts’ expectations of $62.99 million. Equities analysts expect that Maravai LifeSciences will post -0.15 EPS for the current year.

Institutional Trading of Maravai LifeSciences

Several large investors have recently added to or reduced their stakes in MRVI. Zions Bancorporation N.A. acquired a new stake in shares of Maravai LifeSciences in the first quarter worth $28,000. Comerica Bank acquired a new stake in Maravai LifeSciences during the 2nd quarter worth about $180,000. Meeder Asset Management Inc. purchased a new position in shares of Maravai LifeSciences during the 1st quarter valued at about $31,000. Lazard Asset Management LLC lifted its holdings in shares of Maravai LifeSciences by 8,207.5% in the 4th quarter. Lazard Asset Management LLC now owns 3,323 shares of the company’s stock valued at $47,000 after buying an additional 3,283 shares during the period. Finally, Signaturefd LLC boosted its stake in shares of Maravai LifeSciences by 99.9% in the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock worth $34,000 after buying an additional 1,681 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.